FDA CRL - Belcher Pharmaceuticals, LLC

The FDA issued a Complete Response Letter (CRL) to Belcher Pharmaceuticals, LLC. for its New Drug Application (NDA 207987) for Ablysinol (Dehydrated Alcohol Injection, USP), indicating the application could not be approved due to significant deficiencies. Major concerns centered on unresolved chemistry, manufacturing, and controls (CMC) issues, leading to a "withhold" recommendation for the drug substance manufacturing facility, which was also found "not ready for inspection." Specific product quality issues included inadequate drug product specifications, insufficient stability data due to unvalidated analytical methods, and deficiencies in microbiological testing validation. While clinical effectiveness was acknowledged, the application lacked adequate information on instructions for use, especially dosing, and expected adverse event rates. Regulatory actions required Belcher Pharmaceuticals to address all CMC deficiencies, ensure the manufacturing facility is ready for inspection, revise prescribing information to conform with 21 CFR 201.56 and 201.57, update carton and container labels, and provide a comprehensive safety update. Furthermore, the FDA anticipates requiring postmarketing studies under Section 505(o)(3) of the FDCA to analyze potential serious risks upon approval.